A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study†

A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.

(2017) J. Von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

(2012) Seigo Minami et al.   BMC CANCER

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

(2012) Andrea Ardizzoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative determination of erlotinib andO-desmethyl erlotinib in human EDTA plasma and lung tumor tissue

(2012) NAG Lankheet et al.   Bioanalysis

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

(2011) Randeep Sangha et al.   Journal of Thoracic Oncology

Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

(2009) Egbert F. Smit et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies

(2008) E. G. Chiorean et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

(2008) E. Giovannetti et al.   MOLECULAR PHARMACOLOGY